| Alle Patienten | >14 Tage invasive Beatmung | ECMO-Therapie | Verstorbene Patienten | Patienten aus externen Kliniken | ||
|---|---|---|---|---|---|---|
| Patientencharakteristika | ||||||
| Anzahl (%) | 70 (100) | 36 (51,4) | 7 (10) | 20 (28,6) | 19 (27,1) | |
| Alter – Median (IQR) | 66 (57, 74) | 69 (60, 73) | 66 (62, 71) | 69 (64, 79) | 64 (54, 72) | |
| Männlich (%) | 57 (81,4) | 28 (77,8) | 5 (71,4) | 18 (90) | 17 (89,5) | |
| SAPS II bei Aufnahme ICU – Median (IQR) | 62 (48, 69) | 65 (58, 70) | 70 (59, 81) | 68 (62, 81) | 62 (54, 69) | |
| Komorbiditäten | ||||||
| Arterielle Hypertonie (%) | 45 (64,3) | 25 (69,4) | 5 (71,4) | 13 (65) | 12 (63,2) | |
| Koronare Herzerkrankung (%) | 21 (30,0) | 12 (33,3) | 2 (28,6) | 11 (55) | 10 (52,6) | |
| Pulmonale Vorerkrankung (%) | 19 (27,1) | 10 (27,8) | 2 (28,6) | 6 (30) | 5 (26,3) | |
| Nikotinabusus >20 pack years (%) | 11 (15,7) | 7 (19,4) | 2 (28,6) | 2 (10) | 4 (21,1) | |
| Diabetes mellitus (%) | 22 (31,4) | 13 (36,1) | 3 (42,9) | 11 (55) | 9 (47,4) | |
| BMI >30 m2/kg (%) | 20 (28,6) | 14 (38,9) | 3 (42,9) | 5 (25) | 7 (36,8) | |
| Chronische Niereninsuffizienz (%) | 10 (14,3) | 6 (16,7) | 1 (14,3) | 5 (25) | 3 (15,8) | |
| Aktuelle hämatoonkologische Erkrankung (%) | 8 (11,4) | 5 (13,9) | 0 (0,0) | 3 (15,0) | 1 (5,3) | |
| ARDS | ||||||
| Diagnose ARDS (%) | 64 (91,4) | 33 (91,7) | 7 (100) | 19 (95) | 18 (94,7) | |
| Mildes ARDS (%) | 11 (17,2) | 3 (9,1) | 0 (0) | 1 (5,3) | 0 (0,0) | |
| Moderates ARDS (%) | 23 (35,9) | 8 (24,2) | 1 (14,3) | 5 (26,3) | 6 (33,3) | |
| Schweres ARDS (%) | 30 (46,9) | 22 (66,7) | 6 (85,7) | 13 (68,4) | 12 (66,7) | |
| Intensivmedizinische Behandlung | ||||||
| Nichtinvasive Beatmung (%) | 4 (5,7) | 0 (0) | 0 (0) | 0 (0) | 0 (0,0) | |
| Invasive Beatmung | Anzahl (%) | 66 (94,3) | 36 (100) | 7 (100) | 20 (100) | 19 (100,0) |
| Dauer (Tage) – Median (IQR) | 16 (8, 29) | 27 (20, 43) | 22 (17, 27) | 21 (13, 28) | 23 (14, 30) | |
| Aufnahme aus externem Krankenhaus (%) | 19 (27,1) | 14 (38,9) | 4 (57,1) | 9 (45) | 19 (100,0) | |
| Tage bis Verlegung oder Tod – Median (IQR) | 18 (10, 28) | 27 (20, 50) | 21 (16, 22) | 14 (21, 31) | 17 (11, 24) | |
| Tracheotomie (%) | 24 (34,3) | 23 (63,9) | 2 (28,6) | 7 (35) | 9 (47,4) | |
| Bauchlagerung (%) | 31 (44,3) | 20 (55,6) | 7 (100) | 11 (55) | 16 (84,2) | |
| Nierenersatzverfahren wie Hämodialyse/-filtration (%) | 30 (42,9) | 23 (63,9) | 7 (100) | 17 (85) | 10 (52,6) | |
| Antivirale Therapie | ||||||
| Ritonavir + Lopinavir (%) | 4 (5,7) | 2 (5,6) | 0 (0) | 1 (5) | 0 (0,0) | |
| Remdesivir (%) | 1 (1,4) | 0 (0) | 0 (0) | 0 (0) | 0 (0,0) | |
| Favipiravir (%) | 1(1,4) | 1 (2,8) | 1 (14,3) | 1 (5) | 1 (5,3) | |
| Hydroxychloroquin (%) | 36 (51,4) | 18 (50,0) | 4 (57,1) | 11 (55) | 11 (57,9) | |
| Azithromycin (%) | 50 (71,4) | 26 (72,2) | 5 (71,4) | 15 (75) | 11 (57,9) | |
| Rekonvaleszentenplasma (%) | 3 (4,3) | 3 (8,3) | 1 (14,3) | 1 (5) | 1 (5,3) | |
| Interferon‑β (%) | 1 (1,4) | 1 (2,8) | 0 (0) | 1 (5) | 0 (0,0) | |
| Immunmodulatorische Therapie | ||||||
| Methylprednisolon (%) | 18 (25,7) | 11 (30,6) | 3 (42,9) | 7 (35) | 5 (26,3) | |
| Tocilizumab (%) | 6 (8,6) | 4 (11,1) | 3 (42,9) | 3 (15) | 2 (10,5) | |
| Cytosorb® (%) | 13 (18,6) | 10 (27,8) | 5 (71,4) | 10 (50) | 4 (21,1) | |
| Komplikationen im Verlauf | ||||||
| Akutes Leberversagen (%) | 14 (20) | 12 (33,3) | 5 (71,4) | 12 (60) | 8 (42,1) | |
| Thrombembolisches Ereignis (%) | 15 (21,4) | 9 (25) | 1 (14,3) | 6 (30) | 7 (36,8) | |
| Pulmonale Ko‑/Superinfektionen | ||||||
| Bakteriell (%) | 12 (17,1) | 9 (25) | 2 (28,6) | 4 (20) | 4 (21,1) | |
| Viral (%) | 5 (7,1) | 4 (11,1) | 0 (0) | 2 (10) | 2 (10,5) | |
| Fungal (%) (Aspergillus-Spezies) | 5 (7,1) | 4 (11,1) | 1 (14,3) | 4 (20) | 2 (10,5) | |
| Letalität | ||||||
| Verstorben (%) | 20 (28,6) | 14 (38,9) | 6 (85,7) | 20 (100) | 9 (47,4) | |
| Verstorben an COVID-19 (%) | 17 (85) | 13 (92,9) | 6 (100) | 17 (85) | 9 (100,0) | |
| Verstorben mit COVID-19 (%) | 3 (15) | 1 (7,1) | 0 (0) | 3 (15) | 0 (0,0) | |
SAPS „simplified acute physiology score“, BMI Body-Mass-Index, ARDS „acute respiratory distress syndrome“, IQR „interquartile range“, COVID „coronavirus disease“